These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Levodopa + carbidopa + entacapone. Entacapone: a second look: new preparations. Parkinson's disease: a modest effect. Prescrire Int; 2005 Apr; 14(76):51-4. PubMed ID: 15875340 [TBL] [Abstract][Full Text] [Related]
3. [The effect of controlled release of DOPA and carbidopa on clinical response and plasma pharmacokinetics of DOPA in parkinsonian patients]. García de Yébenes J; Mateo D; Pino MA; Cordero M; Pastor M; Chacón J; Morales B; Sánchez V; Mena MA; Giménez Roldán S Neurologia; 1997 Apr; 12(4):145-56. PubMed ID: 9235023 [TBL] [Abstract][Full Text] [Related]
4. [Clozapine in the treatment of adverse psychiatric manifestations of long-term therapy with levodopa]. Svetel MV; Sternić NM; Filipović SR; Vojvodić NM; Kostić VS Srp Arh Celok Lek; 1997; 125(7-8):203-6. PubMed ID: 9304232 [TBL] [Abstract][Full Text] [Related]
5. Multicenter controlled study of Sinemet CR vs Sinemet (25/100) in advanced Parkinson's disease. Hutton JT; Morris JL; Bush DF; Smith ME; Liss CL; Reines S Neurology; 1989 Nov; 39(11 Suppl 2):67-72; discussion 72-3. PubMed ID: 2685652 [TBL] [Abstract][Full Text] [Related]
6. [Early treatment of Parkinson's disease with levodopa]. Odekerken VJ; Post B; Verschuur CV; de Bie RM Ned Tijdschr Geneeskd; 2009; 153():A286. PubMed ID: 19785822 [TBL] [Abstract][Full Text] [Related]
7. [Continuous dopaminergic stimulation by Duodopa in advanced Parkinson's disease: Efficacy and safety]. Annic A; Devos D; Seguy D; Dujardin K; Destée A; Defebvre L Rev Neurol (Paris); 2009; 165(8-9):718-27. PubMed ID: 19150100 [TBL] [Abstract][Full Text] [Related]
8. Concurrent administration of donepezil HCl and levodopa/carbidopa in patients with Parkinson's disease: assessment of pharmacokinetic changes and safety following multiple oral doses. Okereke CS; Kirby L; Kumar D; Cullen EI; Pratt RD; Hahne WA Br J Clin Pharmacol; 2004 Nov; 58 Suppl 1(Suppl 1):41-9. PubMed ID: 15496222 [TBL] [Abstract][Full Text] [Related]
9. New concepts in the treatment of Parkinson's disease. Ahlskog JE; Wilkinson JM Am Fam Physician; 1990 Feb; 41(2):574-84. PubMed ID: 1967895 [TBL] [Abstract][Full Text] [Related]
16. The Sydney multicentre study of Parkinson's disease. The first 18 months. Hely MA; Morris JG; Rail D; O'Sullivan DJ; Williamson PM; Genge S; Reid WG; Broe GA Med J Aust; 1987 Feb; 146(4):195-8. PubMed ID: 3553878 [TBL] [Abstract][Full Text] [Related]
17. Adding a dopamine agonist to preexisting levodopa therapy vs. levodopa therapy alone in advanced Parkinson's disease: a meta analysis. Talati R; Baker WL; Patel AA; Reinhart K; Coleman CI Int J Clin Pract; 2009 Apr; 63(4):613-23. PubMed ID: 19222614 [TBL] [Abstract][Full Text] [Related]
19. Low dose perphenazine and levodopa/carbidopa therapy in a patient with Parkinsonism and a psychotic illness. Hale MS; Bellizzi J J Nerv Ment Dis; 1980 May; 168(5):312-4. PubMed ID: 7365497 [TBL] [Abstract][Full Text] [Related]
20. Sinemet CR in the treatment of patients with Parkinson's disease already on long-term treatment with levodopa. Aarli JA; Gilhus NE Neurology; 1989 Nov; 39(11 Suppl 2):82-5; discussion 95. PubMed ID: 2586767 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]